EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas

Dietmar Krex, Paula Bartmann, Doris Lachmann, Alexander Hagstotz, Willi Jugel, Rosa S Schneiderman, Karnit Gotlib, Yaara Porat, Katja Robel, Achim Temme iD, Moshe Giladi iD, Susanne Michen iD

International Journal of Molecular Sciences · 06.03.2023 · 24 (5) · 5016

DOI: 10.3390/ijms24055016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.03.2023. Verfasst von Dietmar Krex und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novocure® company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor Treating Fields (TTFields) were incorporated into the treatment of glioblastoma, the most malignant brain tumor, after showing an effect on progression-free and overall survival in a phase III clinical trial. The combination of TTFields and an antimitotic drug might further improve this approach. Here, we tested the combination of TTFields with AZD1152, an Aurora B kinase inhibitor, in primary cultures of newly diagnosed (ndGBM) and recurrent glioblastoma (rGBM). AZD1152 concentration was titrated for each cell line and 5–30 nM were used alone or in addition to TTFields (1.6 V/cm RMS; 200 kHz) applied for 72 h using the inovitro™ system. Cell morphological changes were visualized by conventional and confocal laser microscopy. The cytotoxic effects were determined by cell viability assays. Primary cultures of ndGBM and rGBM varied in p53 mutational status; ploidy; EGFR expression and MGMT-promoter methylation status. Nevertheless; in all primary cultures; a significant cytotoxic effect was found following TTFields treatment alone and in all but one, a significant effect after treatment with AZD1152 alone was also observed. Moreover, in all primary cultures the combined treatment had the most pronounced cytotoxic effect in parallel with morphological changes. The combined treatment of TTFields and AZD1152 led to a significant reduction in the number of ndGBM and rGBM cells compared to each treatment alone. Further evaluation of this approach, which has to be considered as a proof of concept, is warranted, before entering into early clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaAntineoplastic AgentsHumansAurora Kinase BNeoplasm Recurrence, LocalOrganophosphatesQuinazolines

Stichwörter der Autor:innen

AZD1152Aurora B kinaseTTFieldsglioblastomaprimary cultures

Substanzen

Aurora Kinase BAntineoplastic Agents2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethy…OrganophosphatesQuinazolines

Autor:innen und Institutionen

  • Department of Neurosurgery, University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany.
  • German Cancer Consortium (DKTK), 01307 Dresden, Germany.
  • National Center for Tumor Diseases (NCT/UCC), 01307 Dresden, Germany.
  • Section Experimental Neurosurgery/Tumor Immunology, Department of Neurosurgery, University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany.
  • Novocure® Ltd., 5 Nahum Het Street, Haifa 31905, Israel.
  • German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

ORCID-Profile: Achim Temme, Moshe Giladi, Susanne Michen

Förderung

  • Novocure® company

Zitieren

APA

Krex, D., Bartmann, P., Lachmann, D., Hagstotz, A., Jugel, W., Schneiderman, R. S., Gotlib, K., Porat, Y., Robel, K., Temme, A., Giladi, M., & Michen, S. (2023). Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas. International Journal of Molecular Sciences, 24(5), 5016. https://doi.org/10.3390/ijms24055016

Vancouver

Krex D, Bartmann P, Lachmann D, Hagstotz A, Jugel W, Schneiderman RS, et al. Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas. International Journal of Molecular Sciences. 2023;24(5):5016. doi:10.3390/ijms24055016

BibTeX
@article{Krex2023,
  author = {Krex, Dietmar and Bartmann, Paula and Lachmann, Doris and Hagstotz, Alexander and Jugel, Willi and Schneiderman, Rosa S and Gotlib, Karnit and Porat, Yaara and Robel, Katja and Temme, Achim and Giladi, Moshe and Michen, Susanne},
  title = {Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {5},
  pages = {5016},
  doi = {10.3390/ijms24055016}
}
Kostenlos starten →